Vaccination with Leishmania mexicana LPG induces PD-1 in CD8+ and PD-L2 in macrophages thereby suppressing the immune response: A model to assess vaccine efficacy  by Martínez Salazar, M.B. et al.
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Leishmania  lipophosphoglycan  (LPG)  is a molecule  that  has  been  used  as  a vaccine  candidate,  with con-
tradictory  results.  Since  unsuccessful  protection  could  be  related  to suppressed  T cell  responses,  we
analyzed the  expression  of inhibitory  receptor  PD-1 in  CD8+ and  CD4+ lymphocytes  and  it  is  ligand
PD-L2  in macrophages  of  BALB/c  mice  immunized  with  various  doses  of Leishmania  mexicana  LPG  and
re-stimulated  in vitro with  different  concentrations  of  LPG.  Vaccination  with  LPG  enhanced  the  expres-
sion  of  PD-1  in CD8+ cells.  Activation  molecules  CD137  were  reduced  in  CD8+ cells  from  vaccinated  mice.
In vitro  re-stimulation  enhanced  PD-L2  expression  in  macrophages  of healthy  mice  in a  dose-dependent
fashion.  The  expression  of PD-1,  PD-L2  and  CD137  is modulated  according  to  the amount  of  LPG  used
during  immunization  and  in vitro  re-stimulation.  We  analyzed  the  expression  of  these  molecules  in  mice
infected with  1  ×  104 or 1 ×  105 L. mexicana  promastigotes  and  re-stimulated  in  vitro  with  LPG. Infection
with 1 ×  105 parasites  increased  the PD-1  expression  in  CD8+ and  diminished  PD-L2 in macrophages.
When  these  CD8+ cells  were  re-stimulated  in  vitro with  LPG,  simulating  a second  exposure  to  parasite
antigens,  PD-1  expression  increased  signiﬁcantly  more,  in  a dose  dependent  fashion.  We  conclude  that
CD8+ T lymphocytes  and macrophages  express  inhibition  molecules  according  to  the concentrations  of
Leishmania  LPG  and to the  parasite  load.  Vaccination  with  increased  amounts  of  LPG  or infections  with
+higher  parasite  numbers  induces  enhanced  expression  of PD-1  and  functional  inactivation  of CD8 cells,
which  can have  critical  consequences  in  leishmaniasis,  since  these  cells  are  crucial  for  disease  control.
These  results  call  for  pre-vaccination  evaluations  of  potential  immunogens,  speciﬁcally  where  CD8  cells
are required,  since  inhibiting  molecules  can  be  induced  after  certain  thresholds  of antigen  concentra-
tions.  We  propose  that  the  analysis  of  PD-1  and  PD-L2  are  useful  tools  to  monitor  the optimal  dose  for
vaccination  candidates.
 201©
. Introduction
Leishmania lipophosphoglycan (LPG), one of the principal
olecules of the parasite, modulates the immune response. LPG
s a ligand for TLR2 in NK cells regulating their IFN- and TNF-
 production [1]. In mast cells and macrophages LPG modulates
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TLR2 and protein kinase-alpha (PKC-), respectively [2,3]. CD4+
lymphocytes deﬁne Leishmania infections, where a Th-1 aids para-
site control and Th-2 response favors disease progression in mouse
models [4]. A major role in the defense against Leishmania is played
by CD8+ cells, both by IFN- production and cytotoxicity [5–7].
Activation of CD8+ and CD4+ lymphocytes is regulated by PD-1,
an inhibition receptor whose two ligands are PD-L1 (B7-H1) and
PD-L2 (B7-DC) [8,9]. The recognition of PD-1 by either ligand leads
to a functional exhaustion of CD8+ lymphocytes, characterized by
reduced proliferation, the absence of cytokine production and a
Open access under CC BY-NC-ND license.failure to exert cytotoxicity [10,11]. Yet some evidence also sug-
gests that these molecules modulate CD8+ cells during Leishmania
mexicana infections. A reduction of CD8+ lymphocytes has been
observed in patients with diffuse cutaneous leishmaniasis (DCL),
 license.
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nfected with L. mexicana. These cells showed enhanced expres-
ion of PD-1 and were hampered in their effectors mechanisms,
eing non-responsive in their cytokine production and showing
imited cytotoxicity, when confronted with autologous Leishmania-
nfected macrophages [12,13]. In a model of experimental chronic
isceral leishmaniasis caused by Leishmania donovani, CD8+ cells
ere found to show phenotypic markers of functional exhaustion
14]. PD-L2 is a ligand for PD-1 displayed on dendritic cells and
acrophages, both of which are host cells for Leishmania [9]. For
rotection against Leishmania infections, a ﬁne-tuned regulation
eading to CD8+ cell activation is crucial, which includes the induc-
ion of co-stimulatory signals and activation molecules such as
D137, favoring cell survival, and the inhibition of PD-1 to avoid
ellular anergy.
LPG has been widely used as a vaccine candidate against
eishmaniasis, with contradicting results. Thus, subcutaneous
mmunization with LPG has failed to protect BALB/c mice against
eishmania amazonensis infections, exacerbating the disease by
nhanced TGF- and IL-10 production [15]. The administration of
nti-LPG antibodies or the intranasal administration of LPG was
hown to revert this effect [16].
One of the main pitfalls during vaccination schemes that end
nsuccessfully is the use of given antigen concentrations, without
revious analysis as to whether this immunogen induces inhibitory
r activation molecules. Furthermore, the diverse protection mod-
ls vary widely in parasite numbers used during the infection
hallenge, which also accounts for possible contradicting results.
o gain insight into the unpredictable outcomes of the different
PG vaccination models, we analyzed if different L. mexicana LPG
oncentrations showed diverse modulation of the inhibitory PD-
 molecule expression in T lymphocytes and PD-L2 expression in
acrophages. Additionally we analyzed the inﬂuence of the para-
ite load on the expression of these molecules.
. Material and methods
.1. Animals
Male BALB/c mice aged to 6–8 weeks were bred and housed at
he animal facilities of the Departamento de Medicina Experimen-
al of the Medical Faculty, UNAM, following the National Ethical
uidelines for Animal Health NOM-062-ZOO-1999 and the guide-
ines recommended for animal care by the Ethical Committee of the
edical School of the UNAM.
.2. Leishmania mexicana culture
L. mexicana parasites were grown in RPMI-1640 medium (Life
echnologies Laboratories, Gaithersburg, MA,  USA), supplemented
ith 10% heat-inactivated FBS at 28 ◦C. Metacyclic promastigotes
ere harvested at late log phase (5 day culture).
.3. Lipophosphoglycan puriﬁcation
Lipophosphoglycan was puriﬁed from L. mexicana as previously
escribed [1].
.4. Vaccination and infection
For vaccination assays, LPG was suspended in sterile PBS at a
nal concentration of 1 g/L.  Mice received three subcutaneous
njections (insulin syringe, needle 31 G BD) in the dorsum contain-
ng 10 or 100 g of LPG or 100 L PBS as control, at a 15 day interval.
he protection assay was carried out 20 days after the last vacci-
ation. Mice were infected subcutaneously (insulin syringe, needlecine 32 (2014) 1259–1265
31 G BD) with 1 × 105 L. mexicana promastigotes in the ear der-
mis. The lesion was  measured weekly with a Vernier. For infection
analysis, non-vaccinated mice were infected with 1 × 104 or 1 × 105
promastigotes and sacriﬁced prior to ulceration of the lesions.
2.5. Peritoneal cells
Mice were sacriﬁced by cervical dislocation. The peritoneal cav-
ity was  infused with 10 mL  of cold sterile PBS pH 7.4 and lightly
massaged. The peritoneal ﬂuid was collected and centrifuged at
800 × g for 10 min  at 4 ◦C. The cells were cultured 2 h in RPMI 1640
(supplemented with 100 U/mL penicillin and 100 IU/mL  strepto-
mycin) containing 10% (v/v) heat-inactivated FBS (RPMI–FBS) at
37 ◦C with 5% CO2. Macrophages (1 × 106/mL) were maintained in
24-well cell culture plates (Corning). Different LPG concentrations
(1, 5 or 10 g) were added, and a negative control contained only
culture medium. After 24 h the cells were harvested and analyzed
by ﬂow cytometry.
2.6. Splenocyte puriﬁcation
The spleen was aseptically removed and placed in a Petri dish
containing cold PBS. The tissue was disrupted in a 100 m nylon
cell strainer (BD Falcon) and the isolated cells were centrifuged at
800 × g for 10 min  at 4 ◦C. Cells were separated by Ficoll–Hypaque
gradient (Sigma) and mononuclear cells were washed twice with
PBS and placed in 6-well plates (Corning) at 5 × 106 cells per well
and stimulated with 1, 5 or 10 g L. mexicana LPG during 24 h.
2.7. Flow cytometry
The extracellular expression of PD-1, CD137, PD-L2 and PD-
L1 was  analyzed in stimulated or non-stimulated peritoneal
macrophages and mononuclear cells (1 × 106 cells/mL) were sus-
pended in 100 L FACS buffer (BD Biosciences cat. 342003)
containing CD16/32 antibodies for 10 min  on ice. After washing,
cells were stained in 50 L FACS buffer containing ﬂuorochrome-
labeled antibodies speciﬁc for CD3e (BD Pharmingen cat. 553066),
CD8a (BD Pharmingen, cat. 551162), CD4 (BD Pharmingen, cat.
552775), CD137 (BD Pharmingen cat. 558976), F4/80 (Biolegend,
cat. 122615), PD-1 (Biolegend, cat. 135205), PD-L1 (Biolegend, cat.
124311), PD-L2 (Biolegend, cat. 107205) or appropriate isotype
controls, for 20 min  on ice. Cells were then washed twice, ﬁxed
in 2% paraformaldehyde and analyzed using a FACSCanto II ﬂow
cytometer equipped with DIVA software (BD Biosciences, USA).
2.8. Statistical analysis
All data are expressed as mean ± SD (standard deviation of
the mean). Comparisons between experimental groups were per-
formed using Mann–Whitney U-test. A value of p < 0.05 was
considered statistically signiﬁcant, using Prism 5 for Mac OS  X®.
Three or more independent experiments were analyzed for three
mice per group.
3. Results
3.1. Vaccination with LPG induces exacerbation and progression
of L. mexicana infection
Our group previously demonstrated that LPG exerts an
immunomodulatory effect on different cells of the immune
response [1–3]. We  were therefore interested in analyzing whether
this molecule could confer protection against L. mexicana infec-
tions. BALB/c mice were vaccinated with 10 g L. mexicana LPG.
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Fig. 1. LPG vaccination does not protect mice from L. mexicana infection. Male
BALB/c were vaccinated at day 0, 15 and 30 with 10 g LPG () or inoculated with
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Fig. 2. LPG modulates the PD-L2 expression in peritoneal macrophages from healthy
BALB/c. (A) Macrophages from peritoneal cavity were isolated and stimulated in vitro
with different concentrations of LPG (1, 5 or 10 g) during 24 h and stained with anti-
PD-L2 mAb  (n = 3). (B) Peritoneal macrophages were isolated and infected in vitro
with Leishmania mexicana promastigotes at a 1:10 ratio (cells:parasites) or with
parasites combined with 5 g LPG. The expression of PD-L1 (white bars) and PD-BS  () and challenged in ear dermis at day 50 with 1 × 105 L. mexicana promastig-
tes.  The infection was followed for 8 weeks and ear lesion was measured weekly.
n  = 4).
wenty days after the third immunization, mice were challenged
n ear dermis with 1 × 105 L. mexicana promastigotes and the infec-
ion was followed throughout 8 weeks. Once the inﬂammation was
etectable, the lesion was measured weekly with a Vernier. Control
ice were injected with 10 L PBS. The ear dermal lesions appeared
rst in non-vaccinated mice around the third week. Lesions of mice
accinated with LPG appeared around the fourth week. Throughout
he course of the infections, both groups of mice showed similar
nﬂammatory lesions (Fig. 1). After 6 weeks, only the vaccinated
ice began to show dissemination of the parasite, forming nodules
n the contralateral earlobe, paws and nose, simulating diffuse cuta-
eous leishmaniasis found in humans (data not shown). Once the
isease disseminated in vaccinated mice, the inﬂammatory lesions
n their earlobes tended to evolve slower after 6–7 weeks of infec-
ion, as compared to non-vaccinated mice (Fig. 1). It remains to
e analyzed whether dissemination increases overall Leishmania
umbers that possibly induce inhibitory molecules on inﬂamma-
ory cells, thereby diminishing the inﬂammation yet not the disease
rogression. These data show that vaccination with LPG induces a
ore rapid dissemination of the parasites.
.2. Macrophages infected in vitro with L. mexicana and
timulated with LPG over-express PD-L2 but show no changes in
D-L1 expression
We  studied the modulation exerted by in vitro stimulation of
acrophages from healthy mice with LPG (1, 5 or 10 g) and ana-
yzed the ligands of regulatory molecules of T cells in macrophages.
timulation with 1 g LPG led to an increased PD-L2 expression, yet
hen the challenge was  augmented to 5 g, the PD-L2 expression
igniﬁcantly increased (3-fold) whereas stimulation with 10 g
nly slightly enhanced the expression (2-fold), which was  not dif-
erent from non-stimulated controls (Fig. 2A). These results suggest
hat LPG is capable of regulating the interaction between T lym-
hocytes and macrophages by inducing PD-L2 in a dose-dependent
ashion.
Furthermore we analyzed whether in vitro infection of
acrophages could regulate the expression of these inhibitoryL2 (black bars) was  analyzed by ﬂow cytometry. The bars represent normalized
data of three separate experiments. Mean ± SD is shown. * p ≤ 0.05 was considered
signiﬁcant.
molecules. Peritoneal macrophages were infected with L. mexi-
cana promastigotes in a ratio 1:10 (cells:parasites). In one group,
Leishmania promastigotes combined with 5 g LPG were used to
infect macrophages. The cells were stained with antibodies against
F4/80, PD-L1 and PD-L2. PD-L1 expression decreased slightly in
macrophages infected with Leishmania promastigotes (Fig. 2B).
In contrast, PD-L2 was up-regulated (2.4-fold) in macrophages
infected with Leishmania combined with LPG, as compared to non-
infected cells (Fig. 2B). In conclusion, LPG stimulation seems to have
a more potent effect to induce PD-L2 in peritoneal macrophages, as
compared to the infection with L. mexicana alone.
3.3. L. mexicana LPG induces PD-1 expression in CD8+ T cells of
vaccinated mice
After ﬁnding that LPG exacerbated disease progression and
modulated the PD-L2 expression in macrophages, we  were inter-
ested in analyzing the effect exerted by LPG on spleen CD8+ and
CD4+ T lymphocytes of mice immunized with two  different doses
of LPG. Vaccination with 10 or 100 g LPG increased PD-1 expres-
sion in CD8+ T cells. Re-stimulation of these cells in vitro with 1, 5 or
10 g LPG maintained their elevated expression of PD-1 (Fig. 3A).LPG had an opposite effect on CD137 expression in CD8+ T cells.
Mice vaccinated with 10 g down-regulated their CD 137 expres-
sion by 20%, whereas vaccination with 100 g decreased CD137
expression by 25% (Fig. 3B). Re-stimulation with 5 or 10 g LPG
1262 M.B. Martínez Salazar et al. / Vaccine 32 (2014) 1259–1265
Fig. 3. PD-1 expression is dose-dependent in BALB/c vaccinated with L. mexicana LPG. Mice were vaccinated three times at 2-week intervals with 10 g (stripped bars) or
100  g LPG (black bars). Non-vaccinated mice were used as controls (white bars). Spleen T lymphocytes were obtained and re-stimulated in vitro with 1, 5 or 10 g LPG
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 cells. (C) PD-1 expression in CD4 T cells, and (D) CD137 expression in CD4 T cells.
p ≤ 0.05 was  considered signiﬁcant.
urther reduced CD137 in mice vaccinated with 10 g, as compared
o non-vaccinated controls (Fig. 3B).
The analysis of CD4+ T cells of mice vaccinated with 10 or 100 g
PG showed no modiﬁcation in the PD-1 expression. Yet in vitro
e-stimulation with 5 or 10 g LPG reduced PD-1 expression in
D4+ cells of mice vaccinated with 10 g, as compared to non-
accinated controls (Fig. 3C). When analyzing the expression of
D137 in CD4+ T cells, mice vaccinated with 10 g mice showed a
educed expression, which diminished even more after these cells
ere re-stimulated in vitro with 10 g LPG (Fig. 3D).
Together these data show that L. mexicana LPG negatively reg-
lates CD8+ cell activation by enhancing PD-1 expression and
oncomitantly reducing CD137 expressions, where the degree of
he modulation depends upon the dose of LPG used for immuniza-
ion as well as the dose of the subsequent stimulus. In contrast
o CD8+ T cells, vaccination with LPG had no inhibitory effect on
D4+ T cells, since it did not modify their PD-1 expression and
e-stimulation with LPG reduced their PD-1 expression. Thus, LPG
accination seems to exert the inhibitory effect only on CD8+ T cells,
n a dose dependent fashion. CD137 antibodies. (A) PD-1 expression in CD8 T cells, (B) CD137 expression in CD8
ars represent normalized data of three separate experiments. Mean ± SD is shown.
3.4. The expression of PD-1 in CD8+ T lymphocytes of mice
infected with L. mexicana is related to parasite load
To analyze whether parasite infection modulates PD-1 expres-
sion in T lymphocytes, BALB/c mice were infected in the earlobe
dermis with 1 × 104 or 1 × 105 L. mexicana promastigotes. Mice
were sacriﬁced prior to ulceration of the lesions. Splenocytes were
isolated and re-stimulated in vitro with 1, 5 or 10 g LPG during
24 h and PD-1 as well as CD137 were analyzed. We  found that PD-1
expression is enhanced in CD8+ T cells of mice infected with 1 × 104
(0.5-fold) or 1 × 105 (3.6-fold) parasites, as compared to CD8+ T cells
from non-infected mice (Fig. 4A). In vitro stimulation with all three
doses of LPG showed the same high expression of PD-1.
The analysis of CD137 in CD8 T cells showed a 40% down-
regulation in mice infected with 1 × 104 promastigotes, whereas
mice infected with 1 × 105 promastigotes showed a similar expres-
sion as non-infected mice. In vitro re-stimulation with LPG did not
alter CD137 expression (Fig. 4B).
CD4+ lymphocytes showed a minimal increase in PD-1 expres-
sion after infections with either number L. mexicana parasites, and
M.B. Martínez Salazar et al. / Vaccine 32 (2014) 1259–1265 1263
Fig. 4. L. mexicana infection promotes the PD-1 expression in CD8 T cells. Mice were infected in the ear dermis ear 1 × 104 (stripped bars) and a second group with 1 × 105
(black bars) L. mexicana promastigotes. Healthy BALB/c mice were used as a control group (white bars). Mice were euthanized before the lesions ulcerated. T cells from spleen
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n  CD8 T cells, (B) CD137 expression in CD8 T cells, (C) PD-1 expression in CD4 T ce
eparate experiments. Mean ± SD is shown. * p ≤ 0.05 was considered signiﬁcant.
howed no changes despite secondary stimuli with LPG (Fig. 4C).
urthermore, the expression of CD137 in CD4+ T cells of infected
ice also remained unaltered. The only up-regulation of this acti-
ation marker was observed in CD4+ T cells of mice infected with
 × 105 parasites after they were re-stimulated in vitro with 5 g
PG (Fig. 4D).
In conclusion these results show that L. mexicana infection
nduces signiﬁcantly enhanced PD-1 expression only in CD8+ T cells,
n a dose-dependent fashion. The reduced expression of CD137 in
ssociation with the increased levels of PD-1 in these CD8+ T cells
eems to indicate that they resemble an exhausted phenotype. PD-1
s minimally expressed in CD4+ cells during L. mexicana infections
nd not altered by in vitro LPG stimuli, showing that L. mexicana
xerts a stronger inhibitory effect on CD8+ T cells, as compared to
D4+ T cells.
.5. Vaccination with LPG or L. mexicana infection of mice
egulates PD-L2 expression in spleen macrophages
Since vaccination with LPG immunomodulated CD8+ T lym-
hocytes toward inhibition, we analyzed if immunization with
ifferent LPG concentrations or infection with different para-
ite numbers also modulated the expression of PD-L2 on spleen
acrophages. Macrophages from mice vaccinated with 10 g LPG stained with anti CD3, CD4, CD8, PD-1 and CD137 antibodies. (A) PD-1 expression
 (D) CD137 expression in CD4 T cells. The bars represent normalized data of three
and re-stimulated in vitro with 1 g LPG, showed diminished
expression of PD-L2 whereas vaccination with 100 g LPG tended
to increase the expression of PD-L2 in macrophages after receiving
secondary stimuli with LPG (Fig. 5A).
Mice infected with 1 × 104 or 1 × 105 parasites down-regulated
PD-L2 expression by 50% (Fig. 5B). Re-stimulation of macrophages
from mice infected with 1 × 104 parasites with LPG always showed
diminished expressions of this inhibitory marker, whereas those
from mice infected with 1 × 105 parasites slightly increase their PD-
L2 expression, albeit never reaching the levels expressed in cells of
non-infected mice (Fig. 5B).
Together, these data show that Leishmania infections reduce
PD-L2 expression in spleen macrophages and that this down-
regulation persists despite secondary in vitro stimulation with LPG.
4. Discussion
Our data shed new light on the cause of enhanced disease pro-
gression after immunization with Leishmania LPG that has also been
reported in the literature [16]. In an attempt to understand the
underlying cause of this unsuccessful vaccination with LPG, we
immunized mice with different concentrations of LPG and there-
after stimulated their spleen cells with various doses of LPG in vitro
in an attempt to simulate a secondary exposure to LPG antigen, as
1264 M.B. Martínez Salazar et al. / Vac
Fig. 5. Analysis of the PD-L2 expression in spleen macrophages from vaccinated
(A)  and infected mice (B). After vaccination with 10 or 100 g LPG or infection
with 1 × 104 or 1 × 105 L. mexicana promastigotes, macrophages were isolated
from the spleen and re-stimulated with 1, 5 or 10 g LPG during 24 h, ﬁxed with
paraformaldehyde and stained for F4/80 and PD-L2. The expression was analyzed
by  ﬂow cytometry. (A) PD-L2 expression in vaccinated animals: white bars repre-
sent healthy mice, stripped bars represent mice vaccinated with 10 g and black
bars are mice vaccinated with 100 g LPG. (B) PD-L2 expression in macrophages
of  mice infected with different parasite numbers. White bars represent healthy
mice, stripped bars are mice infected with 1 × 104 and black bars are mice infected
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mexicana lipophosphoglycan differentially regulates PKCalpha-induced oxida-
tive burst in macrophages of BALB/c and C57BL/6 mice. Parasite Immunolith 1 × 10 L. mexicana promastigotes. The bars represent normalized data of three
eparate experiments. Mean ± SD is shown. * p ≤ 0.05 was  considered signiﬁcant.
ould occur during a natural infection. Additionally, we infected
ice with different L. mexicana numbers and also re-exposed their
ymphocytes to a secondary challenge with LPG. We  here show
hat immunization of BALB/c mice with LPG or infections with L.
exicana promastigotes enhances the expression of the inhibitory
eceptor PD-1 in CD8+, whereas CD4+ T cells remain unaltered. The
ncrease of these inhibitory molecules in CD8+ T cells acts in concert
ith their reduction of the activating molecule CD137, when these
ells are confronted with a new challenge of LPG. These changes
ary according to the amount of the LPG used for the vaccination
nd the parasite load during infection and they also vary according
o the amount of parasite antigen (LPG) encountered by these cells
fter renewed exposure. The combination of these events possibly
eads to a severe down-regulation of the functional capacity of CD8+cine 32 (2014) 1259–1265
T cells in controlling the parasite infection. The response of CD4+ T
cells was  less clear.
PD-1 (programmed-death 1) receptor is related to CD28 and
CTLA-4. It is inducible after T cell activation and down-regulates
activated T cells [11]. Its ligands, PD-L1 and PD-L2, are up-regulated
in APCs following activation [8]. PD-1 and PD-L2 may have distinc-
tive roles in regulating Th-1 and Th-2 responses and reducing T
cell proliferation by arresting the cell cycle [17,18]. This inhibitory
receptor and its ligands have been studied in tumors, showing that
the engagement of PD-1 with PD-L1 and PD-L2 attenuate T cell
responses and help tumor cells escape immunosurveillance [19].
In chronic viral infections, suppressed CD8+ T cell responses have
been attributed to PD-1:PD-L1 interactions [20].
To the best of our knowledge, we here describe for the ﬁrst
time that suppressor receptor PD-1 is induced after vaccination
with elevated doses of Leishmania LPG or with the infection with
elevated amounts of L. mexicana promastigotes. This expression is
speciﬁcally dominant on CD8+ T lymphocytes possibly leading to a
suppression of these cells that are critical in the control of leishman-
iasis, both through IFN- production, as well as in their cytotoxic
effect against autologous Leishmania-infected macrophages [5,6].
These results call for a careful pre-immunization evaluation of
potential vaccination candidates against Leishmania, since the
induction of a suppressive effect can lead to detrimental blockage of
the immune response, favoring a more virulent disease progression.
These data open a new ﬁeld of research in vaccine developments
and provide a novel strategy for therapeutic intervention in leish-
maniasis, where the blockade of PD-1 could represent a valuable
approach for anti-Leishmania immunotherapy.
Our data also yield information on novel parasite evasion strate-
gies, achieving CD8+ T cell suppression, thereby eliminating one of
the more powerful defense mechanisms against L. mexicana [13].
We conclude that vaccination models should assess whether
PD-1 and/or PD-L2 are induced, that, far from activating CD8+ T
cells, it could lead to their inhibition. Additionally, during exper-
imental models of L. mexicana infections, the parasite load must
be taken into account, since it can have opposing effects on PD-
1 expression in lymphocytes. This study provides insight into the
regulatory pathways elicited in vaccine models using different anti-
gen concentrations or during Leishmania infections with different
parasite loads, showing that the outcome can be polarly opposed,
leading to contradictory results.
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